Pharmaceutical Business Review
Anonymous User | Login

Ironwood Enter Into Licencing Agreement With Astellas For Linaclotide

Published: 10-Nov-2009

Astellas, to develop and commercialise linaclotide in Japan, Indonesia, Korea, the Philippines, Taiwan, and Thailand

Ironwood Pharmaceuticals (Ironwood ) and Astellas Pharma have entered into an agreement providing Astellas exclusive rights to develop and commercialise the investigational compound linaclotide in Japan, Indonesia, Korea, the Philippines, Taiwan, and Thailand.

Linaclotide is currently in Phase 3 clinical development in the US for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation. Under the terms of the agreement, Astellas would pay Ironwood $75m in upfront and precommercial milestones, including a $30m licensing fee, as well as escalating royalties on linaclotide sales.

Astellas is expected to lead clinical development in Japan and be responsible for all activities and expenses relating to clinical development, regulatory approval, and commercialisation in the above mentioned territory.

Masafumi Nogimori, president and CEO of Astellas, said: "We are pleased to initiate a great partnership with Ironwood. This collaboration fits well with our existing gastrointestinal franchise in Japan, and I'm excited to deliver linaclotide to the Asian territory. I strongly believe that Astellas will maximise the potential product value of linaclotide with our proven capabilities."

Peter Hecht, CEO of Ironwood, said: "This collaboration continues Ironwood's strategy to form partnerships to develop and commercialise linaclotide in the top three pharmaceutical markets: the US, Europe, and Japan, while enabling Ironwood to retain potentially fifty percent of the long-term global value of linaclotide in those key regions, should linaclotide meet our sales expectations. Astellas has strong capabilities for delivering linaclotide to patients in its territory and we look forward to collaborating with them."

Mail sent successfully

Tell your friend about this article


Please enter a valid email address

Please enter your name

Please enter the mail body


Your Name: *
Your Email: *
Friend's Email: *
Email Body: *
 

Suppliers To This Sector

Browse A-Z

# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

eResearch Technology

Provider of Technology and Services ...

ETS Nederland BV

(Experimental Toxicology Services) ...

ProtNeteomix

Developing Applications for Drug Discovery & Development and Diagnostics ...

ADAPT Localization

The Translation and Localization Specialists ...

Centre for Human Drug Research

Question-Based Drug Development ...

TNO

Pharma Services: From Discovery to the Clinic ...

White Papers

Browse A-Z

# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

GRACO's New FDA Pumps

The Graco 3150 3A sanitary pump is designed to meet the stringent sanitation requirements ...

GRACO's New Hydra-Clean

The Graco 3150 3A sanitary pump is designed to meet the stringent sanitation requirements ...

GRACO's New 1590 & 3150 Pumps

The Graco 3150 3A sanitary pump is designed to meet the stringent sanitation requirements ...

Water Treatment

From the control room to the downstream processing area and with an eye on utilities servi ...

Customer Testimonial – Astra Zeneca

From the control room to the downstream processing area and with an eye on utilities servi ...

Hygienic Processing

From the control room to the downstream processing area and with an eye on utilities servi ...

Related Companies

Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited (Takeda) is a global pharmaceutical company mainl ...

Daiichi Sankyo Company, Ltd

Daiichi Sankyo Company, Ltd (Daiichi Sankyo) is a Japan-based holding company engaged i ...

Kyowa Hakko Kirin Co., Ltd.

Kyowa Hakko Kirin Co., Ltd.(Kyowa Hakoo), formely known as KYOWA HAKKO KOGYO Co., Ltd., ...

Eisai Co., Ltd.

Eisai Co., Ltd. (Eisai) is a Japanese pharmaceutical company focused on researching, de ...

Astellas Pharma Inc.

Astellas Pharma Inc. (Astellas) is a global pharmaceutical company engaged in developin ...

Suppliers Product News

ERT Launches New Online Gateway to Improve Cardiac Safety in Clinical Trials

ERT, a leading provider of centralized ECG, ePRO, eClinical technology and other services to the biopharmaceutical, medical device and related industries, announced today the launch of a unique online web interface – My Study Portal.

ERT Officials Ring the NASDAQ Closing Bell

ERT (NASDAQ: ERES), a leading provider of centralized ECG and eClinical technology, ePRO and other services to the biopharmaceutical, medical device and related industries, closed the stock market on 18 June by ringing the famous NASDAQ bell.

ERT Relocates Customer Care Team to Provide Stronger Client Support

ERT a leading provider of centralized ECG, ePRO, eClinical technology and other services to the biopharmaceutical, medical device and related industries, is to move its dedicated customer care team to its new state-of-the-art headquarters and logistics operations in Philadelphia.

Bridging Studies

A longstanding relationship between J-CLIPNET and CHDR was formalised by signing a Memorandum of Understanding on Nov 16 2009.

Amarna Therapeutics B.V. and TNO Announce SVac Research and Development Partnership

Dutch biotechnology company Amarna Therapeutics B.V. and the Netherlands Organisation for Applied Scientific Research TNO today announced that they have entered into a collaboration agreement to further develop Amarna's viral gene delivery platform SVac.

Free Newsletter Sign-up

Sign up, and we will send you a free Pharmaceutical report on “ Combination Products – Evolution of the Medical Equipment Industry” from GlobalData worth $750

Please enter a valid email address